Blood products leading to the Kingdom of the recycling of raw materials

40 times times!　　Hualan living in 2004 when the IPO price of 15.74 yuan, today's recovery right close to 600 yuan. 4,000 times times!　　Hualan was founded in 1992 with a registered capital of 5 million and now becomes a listed company with a market capitalisation of more than 20 billion. Such a high growth must have a person's performance to ensure that. Hualan in the past 6 years, the annual net profit growth has remained above 50%, the recent 2010.5 annual report shows that the company's net profit growth of up to 300%.　　Blood products and vaccines are the company's two core products, the former is a strong traditional business project, is the cornerstone of rapid growth of company performance, the latter as a new area, the market potential is huge, the future will become the company's new profit growth point. How to become an industry leader from a small factory of obscure blood products? Why are you suddenly involved in the vaccine field while sitting on the top of the blood product? What is the development plan in the field of vaccines?　　With all the questions, the securities Times reporter walked into the fast-growing biopharmaceutical company. Firmly optimistic about the development of the industry "is a patient's family call, patients need to use blood coagulation products, because the local did not sell, the family members of the afternoon to take a plane."　　"Company Dong and deputy general manager Fan Bei received a telephone interrupted the reporter's interview, also side to verify the blood products shortage degree."　　Blood products in the medical field has a life-saving and irreplaceable important position, with High-tech, high investment, high profits and other characteristics, hualan biological blood products gross margin of more than 40%. "The company was founded at the beginning of our blood products industry is still in the initial stage of exploration, there are too many uncertainties in the future, but management after investigation, analysis of the domestic situation after the firm optimistic about the industry, we can do is according to the plan to do the things before, down-to-earth to go on."　　"Fan Bei said. 2001 years later, the blood products industry has been a subversive change, our country no longer allow the new blood products enterprises, making the industry in a monopolistic operation of the state. As the state's regulation is becoming stricter, enterprises that do not meet the requirements are closed down. At present, the production of blood products in China's enterprises have been reduced from more than 30 to now more than 20, and the market demand is strong growth, objectively caused the cake is increasing, and the people who eat cake is decreasing situation.　　Hualan Biology seize the opportunity, rely on the scale advantage quickly occupy the fast growth market, 2004 market every 6 bottles of human blood albumin has hualan biological 1 bottles. Technological transformation to seize the commanding heights "at that time we rely on high quality, large production, medium price into the market, and the market bigger."　　"Fan Bei said. At that time, Hualan biological production of human blood albumin, a product can completely meet the survival and development of the enterprise, the company's income is 90% of human blood albumin.　　But the Watson is not satisfied with the production of a single human blood albumin, which is a large waste of resources, high cost, low technical content of the production model, so the company began to tackle science and technology transformation. Look at the international blood products industry, the production of large-scale, many varieties,High value-added products are the lifeblood of the production of blood products enterprises.　　Through years of independent innovation, the introduction of high-end talent and research and development institutions at home and abroad to cooperate, now hualan in blood products, regardless of size, variety and market share, are stable in the first domestic, can be separated from a bag of 11 varieties of 38 specifications of the product, is the highest comprehensive utilization rate of domestic plasma enterprises. 2008, the country to further improve product quality and strengthen supervision, the 90-day "window period" system for raw plasma, which makes the condition of the blood products in short supply intensified, the slurry cost is gradually raised, and the enterprises with low plasma utilization rate are confronted with the survival crisis of lower interest rate, and Hualan biology relies on its high plasma comprehensive utilization ratio　　, the core technical advantages are exhaustive, thus obtaining a huge profit margin. Mining slurry station resources for the pulp station for blood products Enterprises is the foundation for survival, but also battleground, can say that the number of slurry station directly determines the size of the market share of enterprises.　　Hualan Biology in recent years opened a number of slurry stations, the current number of pulp stations have reached 18, ranked first in the country, so that the growth of the company's blood products have a solid guarantee. Everything seems smooth, in fact, Hualan life has also encountered a difficult period. In 2006, before the reform of the slurry station, each slurry station was established by the Local Health Administration department, and the relationship between the production enterprise and the slurry station was one-to-one, according to the production capacity, the number of pulp stations was determined. After the restructuring, slurry station to the local Health Administration department decoupling, separation of management, slurry station began to become hot.　　Some of the local protection policies let some of the original with the company's counterpart of the pulp station was also divided, and some of the business is on the verge of collapse because of the location of the pulp station was resurrected. "At that time the raw material becomes tense, the enterprise is very anxious, because the blood product enterprise to the plasma raw material dependence is very strong." The company's executives have spent years trying to get to the top of the provinces, and the results are hard to come by today.　　Fan Bei told reporters. Hualan is a Henan enterprise, but the company has long been in the province but not a slurry station.　　2010, through nearly 9 years of unremitting efforts, Hualan biological finally opened in Fengqiu Henan province, the first pulp station, the opening of Henan market for the company's future development has an important strategic significance. It's not accidental. "Blood products have its own industry limitations, the production of raw materials bottlenecks, the selection of vaccines is to reduce risk, expand the industrial chain, is based on the company's strategic adjustment." There is a certain complementarity, some specific immune blood products, need to use vaccines to immunization, some vaccines need to use blood products in the white protein as a protective agent, we have to do the basis of the vaccine. At the same time, the vaccine market has huge space, only take the influenza vaccine as an example, our country inoculation rate is about 1%, far below the developed country inoculation rate 27%.　　Fan Bei explains why he chose to enter the vaccine field. 2005, Hualan Bio-investment has built one of the largest modern vaccine production bases in China. With the first batch of influenza vaccines listed in 2008, the company officially announcedTo enter the vaccine market. In the same year, Wenchuan a big earthquake, Hualan living in the first donated to the disaster area 1 million worth of 36 million yuan flu vaccine.　　The company also created a Chinese influenza vaccine using a single factory with the most density, the shortest time, no serious adverse reactions, such as a number of records, to verify the quality of the company's products, which also for the 2009 swine flu vaccine development, production and vaccination has laid a solid foundation. At that time, China's vaccine market crouching Tiger, Hidden Dragon, foreign large influenza vaccine companies are trying to occupy a certain share in the Chinese influenza vaccine market, especially those who have worked for many years domestic influenza vaccine enterprises, their inherent brand has been recognized by the market, competition is very fierce.　　It turns out that the company's strategy of putting social responsibility and economic interests on an equal footing is right in the early stages of the product market. 2009 swine flu outbreak, corporate social responsibility is heavy, at this time is the vaccine production enterprises to fight the production, quality of an important campaign, the national number of emergency time batches of all production of seasonal influenza vaccine enterprises can develop and produce a swine flu vaccine. Hualan biology as always carry out the big capacity strategy advantages began to highlight, and product quality has undergone more than 2008 years of testing, so the Ministry of Health and the Ministry of Industry dare to occupy nearly 40% of the domestic order to the market to enter the vaccine industry only one year.　　Hualan Biological vaccine products So fame, realize the brand and benefit of the double harvest. "The vaccine market has the suddenness, is unpredictable, takes one production number to be equal to one more opportunity, once has the epidemic situation to have the corresponding product immediately." There is no denying that we are fortunate, but if we do not plan ahead, we will not be able to grasp the opportunity when it comes.　　"Fan Bei said. Hualan said that this year's swine flu vaccine production workshop will not be vacant and would be used to produce seasonal flu vaccines. In addition, the new high standard of influenza workshop will make the company's capacity further increase, but also make our country's influenza prevention and control capacity greatly improved. The company will guide the market through its own propaganda, cooperation with local Government, public service advertisement and so on, raise people's awareness of vaccination, and dig the market of influenza vaccine deeply. Recently, the country has a population under the age of 15 to replant hepatitis B vaccine plan, the market space is huge.　　At present, the Chinese orchid biological hepatitis B vaccine has been produced, the four-price meningitis vaccine has been listed, the future will be launched every year 1-2 new products, and gradually improve the product line, to create a vaccine industry kingdom. Technological innovation for the international paving of China orchid living organisms in the blood products and vaccine products have made remarkable achievements, which is inseparable from the strong research and development capabilities. The company has postdoctoral research workstation and founded the Henan Province Biomedical Engineering Technology Center, composed of a bio-medicine industry elite collection of research and development team. As the domestic blood products, vaccines, genetic engineering and other biological products research, development and production of key High-tech enterprises and state-level innovative pilot enterprises, the company has now formed a research generation, development generation, reserve generation, production generation of continuous developmentMode。 It is worth mentioning that recently, the Hua LAN Biological and the Chinese Academy of Sciences signed a comprehensive science and technology cooperation Agreement.　　This cooperation has greatly enhanced the company's research and development capabilities and the company's core competitiveness, for the future into a more competitive international market ahead of reserve strength. The reporter was fortunate in before leaving, visited the Hualan biological influenza Vaccine production Workshop, neat production with advanced automated production equipment, in the dazzling light, people seem to be in science fiction movies.　　Blond foreign tech experts are working hard, production workshops and laboratories are based on EU standards, which attest to the company's readiness for a truly international path. Hualan, a recent who official came to the company for inspection, while taking the company as a sample to train more than 40 drug inspectors in our country, which is equivalent to who's previous review of Chinese companies. WHO officials are generally satisfied with the results of the inspection, but there is a certain gap between the company's standards and those of the WHO, which is mainly reflected in awareness and management and needs further improvement and refinement. It is believed that in the near future, Hualan biology will take a solid step on the international road.